Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 9
2003 6
2004 3
2005 5
2006 5
2007 8
2008 13
2009 11
2010 11
2011 15
2012 21
2013 9
2014 13
2015 11
2016 12
2017 15
2018 21
2019 21
2020 18
2021 21
2022 28
2023 23
2024 43
2025 62
2026 42

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

387 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean jianhong zhu (281 results)?
Orally Bioavailable Macrocyclic Peptide That Inhibits Binding of PCSK9 to the Low Density Lipoprotein Receptor.
Johns DG, Campeau LC, Banka P, Bautmans A, Bueters T, Bianchi E, Branca D, Bulger PG, Crevecoeur I, Ding FX, Garbaccio RM, Guetschow ED, Guo Y, Ha SN, Johnston JM, Josien H, Kauh EA, Koeplinger KA, Kuethe JT, Lai E, Lanning CL, Lee AYH, Li L, Nair AG, O'Neill EA, Stoch SA, Thaisrivongs DA, Tucker TJ, Vachal P, van Dyck K, Vanhoutte FP, Volckaert B, Wolford DG, Xu A, Zhao T, Zhou D, Zhou S, Zhu X, Zokian HJ, Walji AM, Wood HB. Johns DG, et al. Among authors: zhu x. Circulation. 2023 Jul 11;148(2):144-158. doi: 10.1161/CIRCULATIONAHA.122.063372. Epub 2023 May 1. Circulation. 2023. PMID: 37125593 Free PMC article.
Efficacy and safety of vunakizumab in moderate-to-severe chronic plaque psoriasis: A randomized, double-blind, placebo-controlled phase 3 trial.
Yan K, Li F, Bi X, Han L, Zhang Z, Chen R, Li Y, Zhang L, Wang X, Li L, Lu J, Xu A, Yang S, Lu Y, Sun J, Li Z, Zhu X, Jiang M, Zhang S, Wang W, Li Y, Meng Z, Li H, Mou K, Han X, Li S, Chen A, Li X, Liu D, Zhang C, Ji C, Wang Y, Cheng H, Cui X, Yao X, Bai X, Dong G, Xu J. Yan K, et al. Among authors: zhu x. J Am Acad Dermatol. 2025 Jan;92(1):92-99. doi: 10.1016/j.jaad.2024.09.031. Epub 2024 Sep 26. J Am Acad Dermatol. 2025. PMID: 39332633 Clinical Trial.
Discovery Process of Enlicitide, a Highly Engineered Macrocyclic Peptide Therapeutic, through Issue-Driven Fragment-Based Synthetic Assembly and SAR.
Josien H, Nair AG, Ding FX, Guo Y, Chen YH, Rao AU, Liu J, Tong L, Sun Z, Lo MM, Tucker TJ, Embrey MW, Shahripour A, Wu C, Bianchi E, Branca D, Kuethe JT, Lee J, Thaisrivongs DA, Bulger PG, Zhu X, Ha SN, Johnston JM, Klein DJ, Orth P, Hong MR, Buevich AV, Gao Q, Zokian HJ, Koeplinger KA, Tracy RW, Hafey MJ, Buist N, Bueters T, Alleyne C, Bass A, Campeau LC, Johns DG, Garbaccio RM, Vachal P, Walji A, Wood HB. Josien H, et al. Among authors: zhu x. J Med Chem. 2026 Jun 11;69(11):13473-13491. doi: 10.1021/acs.jmedchem.6c00463. Epub 2026 May 27. J Med Chem. 2026. PMID: 42201324
387 results